


Accepted Manuscript

Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4*H*-benzo[*f*]imidazo [1,5-*a*][1,4] diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA_A receptors: improved bioavailability enhances anticonvulsant efficacy



J.M. Witkin, J.L. Smith, X. Ping, S.D. Gleason, M.M. Poe, G. Li, X. Jin, J. Hobbs, J.M. Schkeryantz, J.S. McDermott, A.I. Alatorre, J.N. Siemian, J.W. Cramer, D.C. Airey, K.R. Methuku, V.V.N.P.B. Tiruveedhula, T.M. Jones, J. Crawford, M.J. Krambis, J.L. Fisher, J.M. Cook, R. Cerne

PII: S0028-3908(18)30205-3
DOI: 10.1016/j.neuropharm.2018.05.006
Reference: NP 7183
To appear in: *Neuropharmacology*
Received Date: 06 August 2017
Revised Date: 29 April 2018
Accepted Date: 03 May 2018

Please cite this article as: J.M. Witkin, J.L. Smith, X. Ping, S.D. Gleason, M.M. Poe, G. Li, X. Jin, J. Hobbs, J.M. Schkeryantz, J.S. McDermott, A.I. Alatorre, J.N. Siemian, J.W. Cramer, D.C. Airey, K. R. Methuku, V.V.N.P.B. Tiruveedhula, T.M. Jones, J. Crawford, M.J. Krambis, J.L. Fisher, J.M. Cook, R. Cerne, Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4*H*-benzo[*f*]imidazo [1,5-*a*][1,4] diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA_A receptors: improved bioavailability enhances anticonvulsant efficacy, *Neuropharmacology* (2018), doi: 10.1016/j.neuropharm.2018.05.006

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4*H*-benzo[*f*]imidazo [1,5-*a*][1,4]diazepine-3-carboxylate (HZ-166) as novel α 2,3 selective potentiators of GABA_A receptors: improved bioavailability enhances anticonvulsant efficacy

J. M. Witkin¹, J. L. Smith³, X. Ping³, S. D. Gleason¹, M. M. Poe², G. Li², X. Jin³, J. Hobbs³, J. M. Schkeryantz¹, J. S. McDermott¹, A. I. Alatorre¹, J. N. Siemian⁴, J.W. Cramer¹, D. C. Airey¹, K. R. Methuku², V. V. N. P. B. Tiruveedhula², T. M. Jones¹, J. Crawford¹, M. J. Krambis¹, J. L. Fisher⁴, J. M. Cook², and R. Cerne¹

¹The Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN

²Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI,

³Indiana University/Purdue University, Riley Hospital, Indianapolis, IN USA

⁴Department of Pharmacology, Physiology & Neuroscience, School of Medicine, University of South Carolina, Columbia, SC USA

Download English Version:

<https://daneshyari.com/en/article/8516519>

Download Persian Version:

<https://daneshyari.com/article/8516519>

[Daneshyari.com](https://daneshyari.com)